Lodinews.com

default avatar
Welcome to the site! Login or Signup below.
|
||
Logout|My Dashboard

Disposable insulin delivery device gives people with type 2 diabetes the freedom to go about their day

Print
Font Size:
Default font size
Larger font size

Posted: Monday, August 6, 2012 10:00 pm | Updated: 1:43 am, Wed Dec 5, 2012.

(BPT) - - Nearly 26 million people in the United States have diabetes and the population continues to grow. There are approximately 5.5 million people in the U.S. who depend on daily insulin injections to help them control and manage their diabetes, but more than half of those people do not achieve their recommended glucose target levels, according to the American Diabetes Association.

The human body needs insulin to be able to fuel the body's cells with glucose. While the body continuously produces insulin, people with type 2 diabetes, the most common form of diabetes, either do not produce enough, or their bodies cannot use the insulin adequately. When there is not enough, or the insulin is not used as it should be, glucose builds up in the blood instead of going into the body's cells. If not controlled properly, diabetes can increase the risk for heart disease, blindness, amputations, stroke and high blood pressure.

"Despite the fact that millions of Americans are on insulin therapy for type 2 diabetes, many of them remain far below their target blood sugar levels," says Dr. Marc Sandberg, medical director at The Center for Nutrition and Diabetes Management, Hunterdon Medical Center. "This is usually because insulin regimens can interfere with daily activities, cause injection pain, and lead to the embarrassment or imposition of injecting medication in public."

Now, a device called the V-Go is paving a new path to insulin delivery for people with type 2 diabetes, all with one simple, disposable device. Made by Valeritas, the V-Go is a simple disposable delivery insulin device that provides a continuous preset rate of insulin (basal) and on-demand dosing at mealtimes (bolus). The V-Go is applied to the skin each day and can be worn underneath clothing allowing individuals to go about their daily routine. Patients wear the V-Go throughout the day and night - even while showering, exercising, and sleeping - then replace it with a new V-Go after a 24-hour period.

The V-Go's novel design can provide insulin the way the body is supposed to. Because of the convenience and simplicity of the design, people with type 2 diabetes may be able to have better control on their insulin regimen and live an active and healthier lifestyle.

Angela Gaskins has lived with diabetes for many years. "It's a relief to find a product that is simple to use and also helps me have more control and flexibility in getting my insulin," she says. "With the V-Go I can go about my daily routine with little interruption of my schedule. This has helped me stick to my treatment regimen, so that I reach my target blood sugar levels better than before."

Valeritas, maker of the device, is committed to helping patients meet their goals and live life on the go. Along with providing 24/7 customer care helpline, Valeritas created an online self-management program called V-Go Life(TM) through a partnership with the diabetes community network, dLife, enabling patients to track their progress and help them maintain better control of their insulin therapy. The program features a comprehensive diabetes lifestyle program including resources like articles, videos, recipes, polls, quizzes and diet and exercise tips. Valeritas is committed to providing its patients with greater access to the product, help with reimbursement and co-pay and co-insurance support.

For more information about the V-Go, or to find out if V-Go is right for you, call 866-881-1209 or visit www.go-vgo.com or www.valeritas.com. Customer care representatives are available 24 hours a day, seven days a week.

Rules of Conduct

  • 1 Use your real name. You must register with your full first and last name before you can comment. (And don't pretend you're someone else.)
  • 2 Keep it clean. Please avoid obscene, vulgar, lewd, racist or sexually oriented language.
  • 3 Don't threaten. Threats of harming another person will not be tolerated.
  • 4 Be truthful. Don't lie about anyone or anything. Don't post unsubstantiated allegations, rumors or gossip that could harm the reputation of a person, company or organization.
  • 5 Be nice. No racism, sexism or any sort of -ism that is degrading to another person.
  • 6 Stay on topic. Make sure your comments are about the story. Don't insult each other.
  • 7 Tell us if the discussion is getting out of hand. Use the 'Report' link on each comment to let us know of abusive posts.
  • 8 Share what you know, and ask about what you don't.

Welcome to the discussion.

    (%remaining%) Remaining Thanks for visiting Lodinews.com. You're entitled to view 20 free articles every 30 days. You will see 10 articles for free before being asked to register, and then you can view 10 additional articles by registering or logging in. Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thanks for visiting Lodinews.com. You're entitled to view 20 free articles every 30 days, and you currently have (%remaining%) free articles remaining ((%remaining_reg%) before being asked to register and (%remaining_sub%) before being asked to subscribe). Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thanks for visiting Lodinews.com. You're entitled to view 20 free articles every 30 days, and you currently have (%remaining%) free articles remaining ((%remaining_reg%) before being asked to register and (%remaining_sub%) before being asked to subscribe). Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thanks for visiting Lodinews.com. You're entitled to view 20 free articles every 30 days, and you currently have (%remaining%) total free articles remaining ((%remaining_reg%) before being asked to register and (%remaining_sub%) before being asked to subscribe). Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thank you for reading Lodinews.com. You have viewed (%viewed%) of your 20 free pages in 30 days. Please login or register at this time and enjoy the next (%remaining%) articles free of charge. After your 20 free articles, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thank you for reading Lodinews.com. Because you have already viewed this article, you may view it again as many times as you would like without subtracting from your remaining free article views.
    (%remaining%) Remaining Thank you for registering on Lodinews.com. You're entitled to view 20 articles for free every 30 days, and you currently have (%remaining%) remaining. Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thank you for reading Lodinews.com. You're entitled to view 20 articles for free every 30 days, and you currently have (%remaining%) remaining. Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thank you for reading Lodinews.com. You're entitled to view 20 articles for free every 30 days, and you currently have (%remaining%) remaining. Then, if you enjoy our site and want full access, we'll ask you to purchase an affordable subscription.
    (%remaining%) Remaining Thank you for reading Lodinews.com. You're entitled to view 20 articles for free every 30 days. This is your last free article this period. On your next article we'll ask you to purchase an affordable subscription.

    Poll

    Loading…

    Regional News

    Mailing List

    Subscribe to a mailing list to have daily news sent directly to your inbox.

    • News Updates

      Would you like to receive our daily news headlines? Sign up now!

    Manage Your Lists